Defining collaborative surveillance to improve decision making for public health emergencies and beyond

[1]  G. Molenberghs,et al.  Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK , 2023, The Lancet.

[2]  A. Tegnell,et al.  Syndemic health crises-The growing role of National Public Health Institutes in shaping a coordinated response. , 2023, The International journal of health planning and management.

[3]  R. Pebody,et al.  How better pandemic and epidemic intelligence will prepare the world for future threats , 2022, Nature Medicine.

[4]  Lars Klareskog,et al.  Towards prevention of autoimmune diseases: The example of rheumatoid arthritis , 2021, European journal of immunology.

[5]  T. Frieden,et al.  Disease surveillance for the COVID-19 era: time for bold changes , 2021, The Lancet.

[6]  W. Greiner,et al.  High-Expenditure Disease in the EU-28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes? , 2021, PharmacoEconomics - Open.

[7]  A. Milewska,et al.  Increasing Co-occurrence of Additional Autoimmune Disorders at Diabetes Type 1 Onset Among Children and Adolescents Diagnosed in Years 2010–2018—Single-Center Study , 2020, Frontiers in Endocrinology.

[8]  L. Arnaud,et al.  Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014. , 2020, Autoimmunity reviews.

[9]  L. Smeeth,et al.  Validation and validity of diagnoses in the General Practice Research Database: a systematic review , 2010, British journal of clinical pharmacology.

[10]  WHO Regional Office for the Eastern Mediterranean , 1995 .